Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

DNLI – Denali Therapeutics Inc.

Float Short %

10.51

Margin Of Safety %

Put/Call OI Ratio

0.28

EPS Next Q Diff

-0.05

EPS Last/This Y

-0.44

EPS This/Next Y

0.18

Price

14.17

Target Price

31.6

Analyst Recom

1.06

Performance Q

-4.92

Relative Volume

0.91

Beta

1.31

Ticker: DNLI




20 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-08-15DNLI14.710.190.001346
2025-08-18DNLI14.810.100.99916
2025-08-19DNLI14.810.340.001522
2025-08-20DNLI14.510.340.001535
2025-08-21DNLI15.230.300.451662
2025-08-22DNLI15.480.300.201677
2025-08-25DNLI15.570.302.221679
2025-08-26DNLI15.560.332.501725
2025-08-27DNLI15.60.341.711730
2025-08-28DNLI15.670.330.201724
2025-08-29DNLI15.280.33999.991733
2025-09-02DNLI15.460.330.151736
2025-09-03DNLI15.270.330.011759
2025-09-04DNLI14.790.310.001852
2025-09-05DNLI15.430.310.001865
2025-09-08DNLI15.510.300.001903
2025-09-09DNLI15.350.300.001909
2025-09-10DNLI14.630.280.222011
2025-09-11DNLI14.820.280.042033
2025-09-12DNLI14.190.280.752037
DateSymbolLastP/C OIP/C VolTotal OI
20 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-08-15DNLI14.71-24.6174.5-3.00
2025-08-18DNLI14.81-24.6180.3-3.00
2025-08-19DNLI14.81-20.179.7-3.00
2025-08-20DNLI14.51-20.193.8-3.00
2025-08-21DNLI15.23-20.140.9-3.00
2025-08-22DNLI15.48-20.166.8-3.01
2025-08-25DNLI15.57-20.174.9-3.01
2025-08-26DNLI15.55-20.179.8-3.01
2025-08-27DNLI15.60-20.176.8-3.01
2025-08-28DNLI15.65-20.176.5-3.01
2025-08-29DNLI15.28-20.196.1-3.01
2025-09-02DNLI15.46-20.169.7-3.01
2025-09-03DNLI15.31-20.1228.0-3.01
2025-09-04DNLI14.78-20.1240.7-3.01
2025-09-05DNLI15.43-20.1201.4-3.01
2025-09-08DNLI15.50-20.1221.2-3.01
2025-09-09DNLI15.35-20.1228.7-3.01
2025-09-10DNLI14.64-20.1247.0-3.01
2025-09-11DNLI14.82-20.1217.2-3.01
2025-09-12DNLI14.17-20.1246.1-3.01
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-08-15DNLI-2.483.7510.14
2025-08-18DNLI-2.483.6610.14
2025-08-19DNLI-2.483.6610.14
2025-08-20DNLI-2.483.6610.14
2025-08-21DNLI-2.483.6610.14
2025-08-22DNLI-2.483.6610.14
2025-08-25DNLI-2.482.5510.14
2025-08-26DNLI-2.482.5510.14
2025-08-27DNLI-2.482.5510.65
2025-08-28DNLI-2.482.5510.65
2025-08-29DNLI-2.482.5510.65
2025-09-02DNLI-2.482.8410.65
2025-09-03DNLI-2.482.8410.65
2025-09-04DNLI-2.482.8410.65
2025-09-05DNLI-2.482.8410.65
2025-09-08DNLI-2.482.8810.65
2025-09-09DNLI-2.482.8810.65
2025-09-10DNLI-2.482.8810.65
2025-09-11DNLI-2.482.8810.87
2025-09-12DNLI-2.482.8810.51
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

-0.72

Avg. EPS Est. Current Quarter

-0.76

Avg. EPS Est. Next Quarter

-0.77

Insider Transactions

-2.48

Institutional Transactions

2.88

Beta

1.31

Average Sales Estimate Current Quarter

1

Average Sales Estimate Next Quarter

5

Fair Value

Quality Score

7

Growth Score

22

Sentiment Score

3

Actual DrawDown %

84.9

Max Drawdown 5-Year %

-87.7

Target Price

31.6

P/E

Forward P/E

PEG

P/S

P/B

2.01

P/Free Cash Flow

EPS

-2.81

Average EPS Est. Cur. Y​

-3.01

EPS Next Y. (Est.)

-2.82

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

0.91

Return on Equity vs Sector %

-71.5

Return on Equity vs Industry %

-58.4

EPS 1 7Days Diff

EPS 1 30Days Diff

0.05

EBIT Estimation

246.1
Denali Therapeutics Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 486
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; DNL343 eIF2B activator program for amyotrophic lateral sclerosis; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
stock quote shares DNLI – Denali Therapeutics Inc. Stock Price stock today
news today DNLI – Denali Therapeutics Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch DNLI – Denali Therapeutics Inc. yahoo finance google finance
stock history DNLI – Denali Therapeutics Inc. invest stock market
stock prices DNLI premarket after hours
ticker DNLI fair value insiders trading